Aquestive Therapeutics Receives U.S. FDA Approval and Market Access for Libervant (diazepam) Buccal Film in Pediatric Patients Ages 2 to 5 and Provides Update on Anaphylm (epinephrine) Sublingual Film
WARREN, N.J. April 29, 2024 - Aquestive Therapeutics, a leading pharmaceutical company focused on innovative science and delivery technologies, has made significant advancements in improving the lives of young patients suffering from epilepsy. The company recently announced that the U.S. Food and Drug Administration (FDA) has approved their product Libervant (diazepam) Buccal Film for the acute treatment of frequent and distinct episodes of seizure activity, often referred to as seizure clusters or acute repetitive seizures, in children between the ages of 2 to 5 who have been diagnosed with epilepsy.
This approval marks a major milestone for Aquestive Therapeutics as it not only expands their market access but also provides an effective solution for an unmet medical need in this specific age group. Currently, there are limited treatment options available for pediatric patients in this age range, making the approval of Libervant an important development in the field of pediatric epilepsy care.
Libervant Buccal Film offers a novel delivery mechanism for diazepam, a commonly used anticonvulsant drug. By utilizing a buccal film, which is placed on the inside of the cheek, Libervant allows for quick absorption, rapid onset of action, and ease of administration, especially in children who may have difficulty swallowing or cooperating during traditional oral medication administration.
The approval of Libervant not only showcases Aquestive Therapeutics’ commitment to developing innovative delivery technologies but also reaffirms their dedication to improving the lives of patients with epilepsy. By providing an effective treatment option for seizure clusters in young children, Aquestive Therapeutics is poised to make a significant impact on the quality of life for both patients and their families.
In addition to the approval of Libervant, Aquestive Therapeutics also provided an update on their product Anaphylm (epinephrine) Sublingual Film. Although no specific details were disclosed, this update suggests that Aquestive is actively working on the development and potential FDA approval of a sublingual film for the treatment of anaphylaxis. This highlights the company’s diverse product pipeline and their commitment to addressing various medical conditions through innovative delivery mechanisms.
Overall, the recent FDA approval of Libervant marks a major achievement for Aquestive Therapeutics. This approval, along with the ongoing development of Anaphylm Sublingual Film, solidifies Aquestive’s position as a leader in innovative pharmaceutical solutions. Through their dedication to improving patients’ lives and leveraging advanced drug delivery technologies, Aquestive Therapeutics is shaping the future of pediatric epilepsy care and potentially revolutionizing the treatment of anaphylaxis.
Comments